论文部分内容阅读
观察柔红霉素对小儿白血病患者的心脏毒性。按所用柔红霉素累积剂量分为第1~4组及未接受化疗白血病患儿的第5组,观察其临床表现,检测心电图、超声心动图(LVEF、FS、E/A)、血清生化指标(CK、CK-MB、cTnI、NT-proBNP、GPBB),进行组间比较。cTnI、NT-proBNP、GPBB在5个组间的差异有统计学意义(P≤0.05),第5组患儿的cTnI、NT-proBNP、GPBB明显高于第1~4组,而上述指标在前4组间的差异无统计学意义。其余指标于5个组间的差异均无统计学意义。小于危险剂量的柔红霉素对白血病患儿的心脏功能无明显毒性作用;尚未接受化疗白血病患儿的心脏功能较已接受包括安全剂量范围柔红霉素在内的化疗药物治疗,并达完全缓解后的患儿差。
To observe the daunorubicin cardiotoxicity in children with leukemia. The cumulative doses of daunorubicin used were divided into groups 1 to 4 and group 5 who did not receive chemotherapy leukemia. The clinical manifestations, electrocardiogram (ECG), echocardiography (EVE), serum biochemistry Indicators (CK, CK-MB, cTnI, NT-proBNP, GPBB) were compared between groups. The differences of cTnI, NT-proBNP and GPBB between the 5 groups were statistically significant (P≤0.05). The cTnI, NT-proBNP and GPBB in group 5 were significantly higher than those in groups 1 to 4, The difference between the first 4 groups was not statistically significant. The remaining indicators in the five groups showed no significant difference. Daunorubicin less than the dangerous dose has no obvious toxic effect on the cardiac function of children with leukemia; the cardiac function of children who have not received chemotherapy leukemia is more complete than the chemotherapy drugs that have received daunorubicin including the safe dose range Alleviating poor children.